The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Combined analysis of retrospective and prospective studies to evaluate the significance of FCα receptor polymorphisms in response to cetuximab plus irinotecan therapy for chemorefractory Japanese patients with advanced and/or metastatic colorectal cancer.
Hideki Shimodaira
No relevant relationships to disclose
Hiroshi Soeda
No relevant relationships to disclose
Keigo Komine
No relevant relationships to disclose
Masahiro Inoue
No relevant relationships to disclose
Masanobu Takahashi
No relevant relationships to disclose
Shin Takahashi
No relevant relationships to disclose
Mika Watanabe
No relevant relationships to disclose
Shunsuke Kato
No relevant relationships to disclose
Makio Gamoh
No relevant relationships to disclose
Chikashi Ishioka
Research Funding - Chugai Pharma; Taiho Pharmaceutical